ICOPMAP SPECIAL EDITION Alternative therapies for Carbapenem-Resistant Enterobacteriaceae (CRE)
DOI:
https://doi.org/10.46542/pe.2025.252.180190Keywords:
Alternative therapy, Antibiotic resistance, Carbapenem, Carbapenem-resistant EnterobacteriaceaeAbstract
Background: Increasing antibiotic resistance is a global concern for human health. Carbapenem antibiotics have high sensitivity and are among the last line of antibiotics for treating infections caused by Gram-negative bacteria that are resistant to various classes of drugs. Over 70% were caused by Carbapenem-Resistant Enterobacteriaceae (CRE) infections, a threat in the clinical field.
Objective: To find alternative antibiotic therapy options for Carbapenem-Resistant Enterobacteriaceae (CRE) infections.
Method: A narrative review method was used in this study. Articles from several journals with the keyword "Therapy Alternative of Carbapenem-Resistant Enterobacteriaceae" in PubMed, Elsevier Article, Cochrane and Indonesian literature from Google Scholar databases were reviewed.
Results: Recommended alternative therapy options for CRE infections include combinations of carbapenem-containing antibiotics with other antibiotic classes as anti-CRE treatments, ceftazidime/avibactam for KPC and OXA-48-producing infections, in vitro efficacy of eravacycline, and prolonged high-dose carbapenem therapy. Additionally, several drugs in the development stages include the combination of new beta-lactamase inhibitor IMI/REL and the novel cephalosporin siderophore cefiderocol, zidebactam, and nacubactam.
Conclusion: New strategies against CRE, such as the reutilization of older antibiotic classes, higher anti-CRE doses, and combination approaches, have demonstrated clinically effective and improved outcomes and have also gained approval from the FDA.
References
Abdallah, M., & Balshi, A. (2018). First literature review of carbapenem-resistant Providencia. New Microbes and New Infections, 25, 16–23. https://doi.org/10.1016/j.nmni.2018.05.009
Amaldi, U., Braccini, S., Codjoe, F. S., Donkor, E. S., Lutgring, J. D., Limbago, B. M., Gadea, F. X., Šavrda, J., Paidarová, I., Yigit, H., Queenan, A. M., Anderson, G. J., Domenech-Sanchez, A., Biddle, J. W., Steward, C. D., Alberti, S., Bush, K., Tenover, F. C., Tooke, C. L., … Paschke, A. (2018). Treatment of infections caused by extended-spectrum-beta-lactamase-, AmpC-, and carbapenemase-producing enterobacteriaceae. Antimicrobial Agents and Chemotherapy, 61(4), 1–11. https://doi.org/10.3855/jidc.11798
Ambler, R. P. (1980). The structure of beta-lactamases. Philosophical Transactions of the Royal Society of London Biological Sciences, 289(1036), 321–331. https://doi.org/10.1098/rstb.1980.0049
Anderson, K. F., Lonsway, D. R., Rasheed, J. K., Biddle, J., Jensen, B., McDougal, L. K., Carey, R. B., Thompson, A., Stocker, S., Limbago, B., & Patel, J. B. (2007). Evaluation of methods to identify the Klebsiella pneumoniae carbapenemase in Enterobacteriaceae. Journal of Clinical Microbiology, 45(8), 2723–2725. https://doi.org/10.1128/JCM.00015-07
Anggraini, D., Sholihin, U. H., Savira, M., Djojosugito, F. A., Irawan, D., & Rustam, R. P. (2018). Prevalence and sensitivity pattern of ESBL-producing Enterobacteriaceae at Arifin Achmad Regional Hospital, Pekanbaru. Jurnal Kedokteran Brawijaya, 30(1), 47–52. https://doi.org/10.21776/ub.jkb.2018.030.01.9
Anthony, K. B., Fishman, N. O., Linkin, D. R., Gasink, L. B., Edelstein, P. H., & Lautenbach, E. (2008). Clinical and microbiological outcomes of serious infections with multidrug-resistant gram-negative organisms treated with tigecycline. Clinical Infectious Diseases, 46(4), 567–570. https://doi.org/10.1086/526775
Asempa, T. E., Motos, A., Abdelraouf, K., Bissantz, C., Zampaloni, C., Nicolau, D. P., Duperchy, E., Bassères, E., Garey, K., Vickers, R., Daigle, D., Hamrick, J., Chatwin, C., Kurepina, N., Kreiswirth, B. N., Shields, R. K., Oliver, A., Clancy, C. J., Nguyen, M. H., Pevear, D. & Xerri, L. (2018). Cefepime/VNRX-5133 broad-spectrum activity is maintained against emerging KPC- and PDC-variants in multidrug-resistant K. pneumoniae and P. aeruginosa. Open Forum Infectious Diseases, 5(1), S419–S420. https://doi.org/10.1093/OFID/OFY210.1201
Aurilio, C., Sansone, P., Barbarisi, M., Pota, V., Giaccari, L. G., Coppolino, F., Barbarisi, A., Passavanti, M. B., & Pace, M. C. (2022). Mechanisms of action of carbapenem resistance. Antibiotics, 11(3), 421. https://doi.org/10.3390/antibiotics11030421
Bassetti, M., & Righi, E. (2014). Eravacycline for the treatment of intra-abdominal infections. Expert Opinion on Investigational Drugs, 23(11), 1575–1584. https://doi.org/10.1517/13543784.2014.965253
Bialek-Davenet, S., Mayer, N., Vergalli, J., Duprilot, M., Brisse, S., Pagès, J. M., & Nicolas-Chanoine, M. H. (2017). In vivo loss of carbapenem resistance by extensively drug-resistant Klebsiella pneumoniae during treatment via porin expression modification. Scientific Reports, 7(1), 1–10. https://doi.org/10.1038/s41598-017-06503-6
Blizzard, T. A., Chen, H., Kim, S., Wu, J., Bodner, R., Gude, C., Imbriglio, J., Young, K., Park, Y. W., Ogawa, A., Raghoobar, S., Hairston, N., Painter, R. E., Wisniewski, D., Scapin, G., Fitzgerald, P., Sharma, N., Lu, J., Ha, S., Hermes, J. & Hammond, M. L. (2014). Discovery of MK-7655, a β-lactamase inhibitor for combination with Primaxin. Bioorganic and Medicinal Chemistry Letters, 24(3), 780–785. https://doi.org/10.1016/j.bmcl.2013.12.101
Boutal, H., Vogel, A., Bernabeu, S., Devilliers, K., Creton, E., Cotellon, G., Plaisance, M., Oueslati, S., Dortet, L., Jousset, A., Simon, S., Naas, T., & Volland, H. (2018). A multiplex lateral flow immunoassay for the rapid identification of NDM-, KPC-, IMP- and VIM-type and OXA-48-like carbapenemase-producing Enterobacteriaceae. Journal of Antimicrobial Chemotherapy, 73(4), 909–915. https://doi.org/10.1093/jac/dkx521
Bulik, C. C., & Nicolau, D. P. (2011). Double-carbapenem therapy for carbapenemase-producing Klebsiella pneumoniae. Antimicrobial Agents and Chemotherapy, 55(6), 3002–3004. https://doi.org/10.1128/AAC.01420-10
Castanheira, M., Deshpande, L. M., Woosley, L. N., Serio, A. W., Krause, K. M., & Flamm, R. K. (2018). Activity of plazomicin compared with other aminoglycosides against isolates from European and adjacent countries, including Enterobacteriaceae molecularly characterised for aminoglycoside-modifying enzymes and other resistance mechanisms. Journal of Antimicrobial Chemotherapy, 73(12), 3346–3354. https://doi.org/10.1093/jac/dky344
Codjoe, F. S., & Donkor, E. S. (2017). Carbapenem resistance: A review. Medical Sciences (Basel, Switzerland), 6(1). https://doi.org/10.3390/medsci6010001
Daikos, G. L., Tsaousi, S., Tzouvelekis, L. S., Anyfantis, I., Psichogiou, M., Argyropoulou, A., Stefanou, I., Sypsa, V., Miriagou, V., Nepka, M., Georgiadou, S., Markogiannakis, A., Goukos, D., & Skoutelis, A. (2014). Carbapenemase-producing Klebsiella pneumoniae bloodstream infections: Lowering mortality by antibiotic combination schemes and the role of carbapenems. Antimicrobial Agents and Chemotherapy, 58(4), 2322–2328. https://doi.org/10.1128/AAC.02166-13
De Jonge, B. L. M., Karlowsky, J. A., Kazmierczak, K. M., Biedenbach, D. J., Sahm, D. F., & Nichols, W. W. (2016). In vitro susceptibility to ceftazidime-avibactam of carbapenem-nonsusceptible enterobacteriaceae isolates collected during the INFORM global surveillance study (2012 to 2014). Antimicrobial Agents and Chemotherapy, 60(5), 3163–3169. https://doi.org/10.1128/AAC.03042-15
De Pascale, G., Montini, L., Pennisi, M. A., Bernini, V., Maviglia, R., Bello, G., Spanu, T., Tumbarello, M., & Antonelli, M. (2014). High-dose tigecycline in critically ill patients with severe infections due to multidrug-resistant bacteria. Critical Care, 18(3), 1–9. https://doi.org/10.1186/cc13858
Doi, Y. (2019). Treatment options for carbapenem-resistant gram-negative bacterial infections. Clinical Infectious Diseases, 69(7), S565–S575. https://doi.org/10.1093/cid/ciz830
Dong, L. T., Espinoza, H. V., & Espinoza, J. L. (2020). Emerging superbugs: The threat of carbapenem-resistant enterobacteriaceae. AIMS Microbiology 6(3), 176–182. https://doi.org/10.3934/microbiol.2020012
Elias, L. S., Konzen, D., Krebs, J. M., & Zavascki, A. P. (2010). The impact of polymyxin B dosage on in-hospital mortality of patients treated with this antibiotic. Journal of Antimicrobial Chemotherapy, 65(10), 2231–2237. https://doi.org/10.1093/jac/dkq285
Fernández, J., Guerra, B., & Rodicio, M. R. (2018). Resistance to carbapenems in non-typhoidal Salmonella enterica serovars from humans, animals and food. Veterinary Sciences, 5(2). https://doi.org/10.3390/vetsci5020040
Gales, A. C., Jones, R. N., & Sader, H. S. (2011). Contemporary activity of colistin and polymyxin B against a worldwide collection of Gram-negative pathogens: Results from the SENTRY antimicrobial surveillance program (2006-09). Journal of Antimicrobial Chemotherapy, 66(9), 2070–2074. https://doi.org/10.1093/jac/dkr239
Giamarellou, H., & Poulakou, G. (2011). Pharmacokinetic and pharmacodynamic evaluation of tigecycline. Expert Opinion on Drug Metabolism and Toxicology, 7(11), 1459–1470. https://doi.org/10.1517/17425255.2011.623126
Gunawan, S., Tjandra, O., & Halim, S. (2021). Education on the rational use of antibiotics in the state vocational school 1 Tambelang, Bekasi, Environment. https://doi.org/10.24912/jbmi.v4i1.11925
Haidar, G., Clancy, C. J., Chen, L., Samanta, P., Shields, R. K., Kreiswirth, B. N., & Nguyen, H. (2017). Identifying spectra of activity and therapeutic niches for ceftazidime-avibactam and imipenem-relebactam against carbapenem-resistant Enterobacteriaceae. Antimicrobial Agents and Chemotherapy, 61(9), e00642–17. https://www.doi/10.1128/AAC.00642-17
Haley J., Morrill, Jason M. Pogue, Keith S. Kaye, and K. L. L. (2015). Treatment options for carbapenem-resistant Enterobacteriaceae infections, 2. https://doi.org/10.1093/ofid/ofv05
Halim, S. V., Yulia, R., & Setiawan, E. (2017). Carbapenem utilisation among adult inpatients in one private hospital in Surabaya. Indonesian Journal of Clinical Pharmacy, 6(4), 267–281. https://doi.org/10.15416/ijcp.2017.6.4.267
Hossain, A., Ferraro, M. J., Pino, R. M., Dew, R. B., Moland, E. S., Lockhart, T. J., Thomson, K. S., Goering, R. V., & Hanson, N. D. (2004). Plasmid-mediated carbapenem-hydrolysing enzyme KPC-2 in an Enterobacter sp. Antimicrobial Agents and Chemotherapy, 48(11), 4438–4440. https://doi.org/10.1128/AAC.48.11.4438-4440.2004
Karaiskos, I., Galani, I., Souli, M., & Giamarellou, H. (2019a). Novel β-lactam-β-lactamase inhibitor combinations: Expectations for the treatment of carbapenem-resistant Gram-negative pathogens, 15(2), 133–149. https://doi.org/10.1080/17425255.2019.1563071
Karaiskos, I., Lagou, S., Pontikis, K., Rapti, V., & Poulakou, G. (2019b). The “Old” and the “New” antibiotics for MDR Gram-negative pathogens: For whom, when, and how. Frontiers in Public Health, 7, 1–25. https://doi.org/10.3389/fpubh.2019.00151
Leavitt, A., Navon-Venezia, S., Chmelnitsky, I., Schwaber, M. J., & Carmeli, Y. (2007). Emergence of KPC-2 and KPC-3 in carbapenem-resistant Klebsiella pneumoniae strains in an Israeli hospital. Antimicrobial Agents and Chemotherapy, 51(8), 3026–3029. https://doi.org/10.1128/AAC.00299-07
Lee, C. M., Lai, C. C., Chiang, H. T., Lu, M. C., Wang, L. F., Tsai, T. L., Kang, M. Y., Jan, Y. N., Lo, Y. T., Ko, W. C., Tseng, S. H., & Hsueh, P. R. (2017). Presence of multidrug-resistant organisms in the residents and environments of long-term care facilities in Taiwan. Journal of Microbiology, Immunology and Infection, 50(2), 133–144. https://doi.org/10.1016/j.jmii.2016.12.001
Lee, J., Patel, G., Huprikar, S., Calfee, D. P., & Jenkins, S. G. (2009). Decreased susceptibility to polymyxin B during treatment for carbapenem-resistant Klebsiella pneumoniae infection. Journal of Clinical Microbiology, 47(5), 1611–1612. https://doi.org/10.1128/JCM.02466-08
Lesho, E. P., & Laguio-Vila, M. (2019). The slow-motion catastrophe of antimicrobial resistance and practical interventions for all prescribers. Mayo Clinic Proceedings, 94(6), 1040–1047. https://doi.org/10.1016/j.mayocp.2018.11.005
Lomovskaya, O., Sun, D., Rubio-Aparicio, D., Nelson, K., Tsivkovski, R., Griffith, D. C., & Dudley, M. N. (2017). Vaborbactam: Spectrum of beta-lactamase inhibition and impact of resistance mechanisms on activity in enterobacteriaceae. Antimicrobial Agents and Chemotherapy, 61(11). https://doi.org/10.1128/AAC.01443-17
Machuca, I., Gutiérrez-Gutiérrez, B., Gracia-Ahufinger, I., Rivera Espinar, F., Cano, Á., Guzmán-Puche, J., Pérez-Nadales, E., Natera, C., Rodríguez, M., León, R., Castón, J. J., Rodríguez-López, F., Rodríguez-Baño, J., & Torre-Cisneros, J. (2017). Mortality associated with bacteremia due to colistin-resistant Klebsiella pneumoniae with high-level meropenem resistance: Importance of combination therapy without colistin and carbapenems. Antimicrobial Agents and Chemotherapy, 61(8), e00406-17. https://www.doi/10.1128/AAC.00406-17.
Miriagou, V., Cornaglia, G., Edelstein, M., Galani, I., Giske, C. G., Gniadkowski, M., Malamou-Lada, E., Martinez-Martinez, L., Navarro, F., Nordmann, P., Peixe, L., Pournaras, S., Rossolini, G. M., Tsakris, A., Vatopoulos, A., & Cantón, R. (2010). Acquired carbapenemases in Gram-negative bacterial pathogens: Detection and surveillance issues. Clinical Microbiology and Infection, 16(2), 112–122. https://doi.org/10.1111/j.1469-0691.2009.03116.x
Monogue, M. L., Giovagnoli, S., Bissantz, C., Zampaloni, C., & Nicolau, D. P. (2018). In vivo efficacy of meropenem with a novel non--lactam–-lactamase inhibitor, nacubactam, against gram-negative organisms exhibiting various resistance mechanisms in a murine complicated urinary tract infection model. Antimicrobial Agents and Chemotherapy, 62(9). https://doi.org/10.1128/AAC.02596-17
Motsch, J., De Oliveira, C. U. M., Stus, V., Kö Ksal, I., Lyulko, O., Boucher, H. W., Kaye, K. S., File, T. M., Brown, M. L., Khan, I., Du, J., Joeng, H. K., Tipping, R. W., Aggrey, A., Young, K., Kartsonis, N. A., Butterton, J. R., & Paschke, A. (2020). RESTORE-IMI 1: A multicentre, randomised, double-blind trial comparing efficacy and safety of imipenem/relebactam vs colistin plus imipenem in patients with imipenem-nonsusceptible bacterial infections. Clinical Infectious Diseases, 70(9), 1799–1808. https://doi.org/10.1093/cid/ciz530
Ni, W., Han, Y., Liu, J., Wei, C., Zhao, J., Cui, J., Wang, R., & Liu, Y. (2016). Tigecycline treatment for carbapenem-resistant enterobacteriaceae infections: A systematic review and meta-analysis. Medicine (United States), 95(11). https://doi.org/10.1097/MD.0000000000003126
Nordmann, P., Cuzon, G., & Naas, T. (2009). The real threat of Klebsiella pneumoniae carbapenemase-producing bacteria. The Lancet Infectious Diseases, 9(4), 228–236. https://doi.org/10.1016/S1473-3099(09)70054-4
Okoche, D., Asiimwe, B. B., Katabazi, F. A., Kato, L., & Najjuka, C. F. (2015). Prevalence and characterisation of carbapenem-resistant enterobacteriaceae isolated from Mulago National Referral Hospital, Uganda. PLoS ONE, 10(8), 1–11. https://doi.org/10.1371/journal.pone.0135745
Oliva, A., Scorzolini, L., Castaldi, D., Gizzi, F., De Angelis, M., Storto, M., D’Abramo, A., Aloj, F., Mascellino, M. T., Mastroianni, C. M., & Vullo, V. (2017). Double-carbapenem regimen, alone or in combination with colistin, in the treatment of infections caused by carbapenem-resistant Klebsiella pneumoniae (CR-Kp). Journal of Infection, 74(1), 103–106. https://doi.org/10.1016/j.jinf.2016.10.002
Papp-Wallace, K. M., Nguyen, N. Q., Jacobs, M. R., Bethel, C. R., Barnes, M. D., Kumar, V., Bajaksouzian, S., Rudin, S. D., Rather, P. N., Bhavsar, S., Ravikumar, T., Deshpande, P. K., Patil, V., Yeole, R., Bhagwat, S. S., Patel, M. V., Van Den Akker, F., & Bonomo, R. A. (2018). Strategic approaches to overcome resistance against Gram-Negative pathogens using β-lactamase inhibitors and β-lactam enhancers: Activity of three novel diazabicyclooctanes WCK 5153, Zidebactam (WCK 5107), and WCK 4234. Journal of Medicinal Chemistry, 61(9), 4067–4086. https://doi.org/10.1021/acs.jmedchem.8b00091
Peleg, A. Y., Franklin, C., Bell, J. M., & Spelman, D. W. (2005). Dissemination of the metallo-β-lactamase gene blaIMP-4 among gram-negative pathogens in a clinical setting in Australia. Clinical Infectious Diseases, 41(11), 1549–1556. https://doi.org/10.1086/497831
Pérez-Gracia, B. S.-G. and M. T. (2019). Present and future of Carbapenem-Resistant Enterobacteriaceae (CRE) Infections. AIP Conference Proceedings, 827, 248–261. https://doi.org/10.1063/1.2195216
Petty, L. A., Henig, O., Patel, T. S., Pogue, J. M., & Kaye, K. S. (2018). Overview of meropenem-vaborbactam and newer antimicrobial agents for the treatment of carbapenem-resistant enterobacteriaceae. Infection and Drug Resistance, 11, 1461–1472. https://doi.org/10.2147/IDR.S150447
Putra, O. N., Doso Saputro, I., & Faizah, A. K. (2020). Case report: Expanded-spectrum beta lactamase-producing Klebsiella pneumoniae in burn injury with hospital-acquired pneumonia. Pharmaceutical Journal of Indonesia, 5(2), 79–83. https://doi.org/10.21776/ub.pji.2020.005.02.2
Qu, X., Wang, H., Chen, C., Tao, Z., Yin, C., Yin, A., Ma, C., & Idris, A. (2019). Surveillance of carbapenem-resistant Klebsiella pneumoniae in Chinese hospitals - A five-year retrospective study. Journal of Infection in Developing Countries, 13(12), 1101–1107. https://doi.org/10.3855/jidc.11798
Queenan, A. M., Shang, W., Flamm, R., & Bush, K. (2010). Hydrolysis and inhibition profiles of β-lactamases from molecular classes A to D with doripenem, imipenem, and meropenem. Antimicrobial Agents and Chemotherapy, 54(1), 565–569. https://doi.org/10.1128/AAC.01004-09
Qureshi, Z. A., Paterson, D. L., Potoski, B. A., Kilayko, M. C., Sandovsky, G., Sordillo, E., Polsky, B., Adams-Haduch, J. M., & Doi, Y. (2012). Treatment outcome of bacteremia due to KPC-producing Klebsiella pneumoniae: Superiority of combination antimicrobial regimens. Antimicrobial Agents and Chemotherapy, 56(4), 2108–2113. https://doi.org/10.1128/AAC.06268-11
Rodríguez-Baño, J., Gutiérrez-Gutiérrez, B., Machuca, I., & Pascual, A. (2018). Treatment of infections caused by extended-spectrum-Beta-Lactamase-, AmpC-, and Carbapenemase-producing Enterobacteriaceae. Clinical microbiology reviews, 31(2), e00079-17. https://doi.org/10.1128/CMR.00079-17
Sader, H. S., Castanheira, M., Duncan, L. R., & Flamm, R. K. (2018). Antimicrobial susceptibility of Enterobacteriaceae and Pseudomonas aeruginosa isolates from United States Medical Centres stratified by infection type: Results from the International Network for Optimal Resistance Monitoring (INFORM) surveillance program, Diagnostic Microbiology and Infectious Disease, 92(1), 69–74. https://doi.org/10.1016/j.diagmicrobio.2018.04.012
Saisho, Y., Katsube, T., White, S., Fukase, H., & Shimada, J. (2018). Pharmacokinetics, safety, and tolerability of cefiderocol, a novel siderophore cephalosporin for Gram-Negative bacteria. Healthy Subjects, 62(3), e02163-17. https://doi.org/10.1128/AAC.02163-17
Santoso, I., & Rostinawati, T. (2022). Review: Development of Meropenem Antibiotic Resistance against Pseudomonas aeruginosa, Acinetobacter baumannii, and Klebsiella pneumoniae bacteria in Indonesia. Pharmacy, 20(3), 123–134. https://jurnal.unpad.ac.id/farmaka/article/view/40708
Shields, R. K., Nguyen, H., Chen, L., Press, E. G., Potoski, B. A., Marini, R. V., Doi, Y., Kreiswirth, B. N., & Clancy, C. J. (2017). Ceftazidime-Avibactam is superior to other ttreatment regimens against Carbapenem-Resistant Klebsiella pneumoniae bacteraemia. Antimicrobial Agents and Chemotherapy, 61,10. https://doi.org/10.1128/aac.00883-17
Tilahun, M., Kassa, Y., Gedefie, A., & Ashagire, M. (2021). Emerging carbapenem-resistant enterobacteriaceae infection, its epidemiology and novel treatment options: A review. Infection and Drug Resistance, 14, 4363–4374. https://doi.org/10.2147/IDR.S337611
Ting, S. W., Lee, C. H., & Liu, J. W. (2018). Risk factors and outcomes for the acquisition of carbapenem-resistant Gram-negative bacillus bacteremia: A retrospective propensity-matched case control study. Journal of Microbiology, Immunology and Infection, 51(5), 621–628. https://doi.org/10.1016/j.jmii.2016.08.022
Tooke, C. L., Hinchliffe, P., Bragginton, E. C., Colenso, C. K., Hirvonen, V. H. A., Takebayashi, Y., & Spencer, J. (2019). β-Lactamases and β-Lactamase inhibitors in the 21st century. Journal of Molecular Biology, 431(18), 3472–3500. https://doi.org/10.1016/j.jmb.2019.04.002
Trecarichi, E. M., & Tumbarello, M. (2017). Therapeutic options for carbapenem-resistant Enterobacteriaceae infections. Virulence, 8(4), 470–484. https://doi.org/10.1080/21505594.2017.1292196
van Duin, D., & Doi, Y. (2017). The global epidemiology of carbapenemase-producing Enterobacteriaceae. Virulence, 8(4), 460–469. https://doi.org/10.1080/21505594.2016.1222343
van Duin, D., Lok, J. J., Earley, M., Cober, E., Richter, S. S., Perez, F., Salata, R. A., Kalayjian, R. C., Watkins, R. R., Doi, Y., Kaye, K. S., Fowler, V. G., Paterson, D. L., Bonomo, R. A., & Evans, S. (2018). Colistin versus Ceftazidime-Avibactam in the treatment of infections due to Carbapenem-Resistant Enterobacteriaceae. Clinical Infectious Diseases, 66(2), 163–171. https://doi.org/10.1093/cid/cix783
Vardakas, K. Z., Legakis, N. J., Triarides, N., & Falagas, M. E. (2016). Susceptibility of contemporary isolates to fosfomycin: a systematic review of the literature. International Journal of Antimicrobial Agents, 47(4), 269–285. https://doi.org/10.1016/j.ijantimicag.2016.02.001
Ventola, C. L. (2015). The antibiotic resistance crisis: Part 1: Causes and threats. P & T: a peer-reviewed journal for formulary management, 40(4), 277–283. https://pmc.ncbi.nlm.nih.gov/articles/PMC4378521/
Venugopalan, V., Nogid, B., Le, T. N., Rahman, S. M., & Bias, T. E. (2017). Double carbapenem therapy (DCT) for bacteremia due to carbapenem-resistant Klebsiella pneumoniae (CRKP): From test tube to clinical practice. Infectious Diseases, Taylor and Francis Ltd, 49(11–12), 867–870). https://doi.org/10.1080/23744235.2017.1350880
Vicari, G., Bauer, S. R., Neuner, E. A., & Lam, S. W. (2013). Association between colistin dose and microbiologic outcomes in patients with multidrug-resistant gram-negative bacteremia. Clinical Infectious Diseases, 56(3), 398–404. https://doi.org/10.1093/cid/cis909
Walkty, A., Adam, H., Baxter, M., Denisuik, A., Lagacé-Wiens, P., Karlowsky, J. A., Hoban, D. J., & Zhanel, G. G. (2014). In vitro activity of plazomicin against 5,015 gram-negative and gram-positive clinical isolates obtained from patients in Canadian hospitals as part of the CANWARD study, 2011-2012. Antimicrobial Agents and Chemotherapy, 58(5), 2554–2563. https://doi.org/10.1128/AAC.02744-13
Walsh, T. R., Toleman, M. A., Poirel, L., & Nordmann, P. (2005). Metallo-β-lactamases: The quiet before the storm? Clinical Microbiology Reviews, 18(2), 306–325. https://doi.org/10.1128/CMR.18.2.306-325.2005
Weston, N., Sharma, P., Ricci, V., & Piddock, L. J. V. (2017). Regulation of the AcrAB-TolC efflux pump in Enterobacteriaceae. Research in Microbiology, 169(7–8), 425–431. https://doi.org/10.1016/J.RESMIC.2017.10.005
Zhanel, G. G., Cheung, D., Adam, H., Zelenitsky, S., Golden, A., Schweizer, F., Gorityala, B., Lagacé-Wiens, P. R. S., Walkty, A., Gin, A. S., Hoban, D. J., & Karlowsky, J. A. (2016). Review of eravacycline, a novel fluorocycline antibacterial agent. Drugs, 76(5), 567–588. https://doi.org/10.1007/s40265-016-0545-8
